Eli Lilly Q4 miss brings buying opportunity, says JPMorgan

JPMorgan analyst Chris Schott says Eli Lilly’s (LLY) Q4 miss represents a buying opportunity as the company is positioned for strong growth in 2025. The company’s 2025 sales guidance incorporates expectations for growth tailwinds from its expanded label and geographic footprint, sellable doses of incretins to increase at least 60% year-over-year in the first half, and no major changes in U.S. Zepbound pricing dynamics, the analyst tells investors in a research note. JPMorgan attributes the Q4 miss to lower than expected wholesaler volumes and inventory stocking as well as seasonality dynamics for Mounjaro. It keeps an Overweight rating on Eli Lilly.